Maternal use of loperamide in early pregnancy and delivery outcome

doi:10.1111/j.1651-2227.2008.00718.x

If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.

It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.

Wiley InterScience

Acta Pædiatrica

Volume 97 Issue 5, Pages 541 - 545

Published Online: 3 Apr 2008

Published on behalf of

Go to Society Site

< Previous Abstract | Next Abstract >

Save Article to My Profile Download Citation Request Permissions

REGULAR ARTICLES

Maternal use of loperamide in early pregnancy and delivery outcome

Bengt Källén ¹ , Emma Nilsson ² , Petra Otterblad Olausson ²

1.Tornblad Institute, University of Lund, Lund, Sweden 2.National Board of Health and Welfare, Centre for Epidemiology, Stockholm, Sweden

Correspondence
Professor Bengt Källén, Tornblad Institute, Biskopsgatan 7, SE-223 62 Lund, Sweden. Tel: +46-46-222-7536 | Fax: +46-46-222-4226 | Email: Bengt.Kallen@med.lu.se

KEYWORDS

Congenital malformations • Loperamide • Pregnancy

ABSTRACT

Aim: To study delivery outcome including presence of infant congenital malformations after maternal use of loperamide in early pregnancy.

Methods: Using the Swedish Medical Birth Register, women reporting the use of loperamide in early pregnancy were compared with other women for the period July 1, 1995–2004. Odds ratios (OR) or risk ratios (RR) were estimated after adjustment for some variables, which were associated with the use of loperamide (year of delivery, maternal age, parity, smoking, number of previous miscarriages).

Results: Characteristics of women using loperamide in early pregnancy were identified. An analysis of concomitant drug use indicated that only few of the women had inflammatory bowel disease. The risk of any congenital malformation was increased (OR = 1.43, 95% CI 1.04–1.96), based on 43 cases, but no major contributing type could be identified. The risk of hypospadias was significantly increased (RR = 3.2, 95% CI 1.3–6.6), based on seven cases. A statistically significant increase was seen also for placenta previa, large for gestational age and caesarean section.

Conclusion: Maternal use of loperamide in early pregnancy may be associated with a moderate risk increase for a malformation in the infant. The finding should be evaluated from other large studies.

Received
9 October 2007; revised 8 January 2008; accepted 10 January 2008

DIGITAL OBJECT IDENTIFIER (DOI)

10.1111/j.1651-2227.2008.00718.x About DOI